Skip to content
naulon
Not checkedNot checked for notices yet.

Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies

Bastian Steuwer, Euzebiusz Jamrozik, Nir Eyal

International Journal of Infectious Diseases · 2021

doi:10.1016/j.ijid.2021.02.038 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The design of human challenge studies balances scientific validity, efficiency and study safety. This Perspective explores some advantages and disadvantages of ‘low-dosage’ challenge studies, in the setting of testing second-generation vaccines against COVID-19. Compared with a conventional vaccine challenge, a low-dosage vaccine challenge would be more likely to start, and start earlier. A low-dosage challenge would also be less likely to rule out a vaccine candidate that would have potentially been effective, particularly in certain target uses. A key ethical advantage of a low-dosage challenge over a conventional challenge is that both it and its dose escalation process are safer for each participant. Low-dosage studies would require larger numbers of participants than conventional challenges, but this and other potential disadvantages are less serious than they may initially appear. Overall, low-dosage challenges should be considered for certain roles such as prioritizing between second-generation vaccines against COVID-19.

Abstract licence: CC BY-NC-ND

References36

  1. 19.
  2. 20.
  3. 31.

33 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.